Topical imiquimod as good as surgery for vulvar intraepithelial neoplasia: trial
The immune response modifier can be considered first-line treatment in women likely to stick with it, doctors suggest
Topical imiquimod works just as well as surgery for the first-line treatment of vulvar high-grade squamous intraepithelial lesions, according to a phase III non-inferiority trial.
Results from the multicentre Austrian study also showed no significant difference in rates of HPV clearance, adverse events or treatment satisfaction, the researchers say.
